Inflammatory pathways (modulation) (null)

"Inflammatory pathways modulation" does not refer to a single molecule, receptor, or defined molecular target, but rather to the broad modulation of multiple intracellular signaling cascades and molecular interactions involved in the immune and inflammatory response. These pathways include central nodes such as the nuclear factor kappa-B (NF-κB) pathway, mitogen-activated protein kinase (MAPK) pathways, Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathways, as well as the inflammasome complexes. Key targets for intervention within these pathways are typically specific enzymes, receptors, or protein-protein interactions mediating the effects of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α, or sensors like TLRs and various transcription factors. Therapeutic modulation of these pathways is foundational in the treatment of a wide range of inflammatory diseases and some cancers; however, "inflammatory pathways modulation" as a term is not a canonical drug target, receptor, or enzyme. Instead, it refers to a therapeutic principle or strategy, not a specific, characterizable molecular entity. Therapeutic drugs such as canakinumab (IL-1β inhibitor), anakinra (IL-1 receptor antagonist), dorzolamide (disrupts the MAL–PKCδ interaction), and gefitinib (inhibits MAL–c-Jun interaction) are examples of agents that affect components of inflammatory pathways. Modulating these pathways, especially key nodes like NF-κB and the inflammasome, can reduce pathological inflammation, but may lead to immunosuppression and increased infection risk. Generally, monitoring involves cytokine and acute-phase reactant levels, while major safety concerns for pathway-targeting agents include susceptibility to infections and potential hematologic toxicity. In summary, "inflammatory pathways modulation" is not a precise single target but encompasses numerous molecular targets within innate and adaptive immune signaling, and should not be used as the canonical target name for structured drug target information.

Other names

Inflammation modulationInflammatory signaling pathwaysModulation of inflammatory signalingInflammatory pathway modulation

Inhibition of cytokine signaling (e.g., IL-1, IL-6, TNF-α); Disruption of protein-protein interactions in signaling complexes (e.g., MAL–PKCδ, MAL–c-Jun); Inhibition of inflammasome activation